Combination cancer immunotherapies: Emerging treatment strategies adapted to the tumor microenvironment
N Kirchhammer, MP Trefny, P Auf der Maur… - Science translational …, 2022 - science.org
Science translational medicine, 2022•science.org
Immune checkpoint blockade (ICB) has revolutionized cancer treatment. However,
resistance to ICB occurs frequently due to tumor-intrinsic alterations or extrinsic factors in the
tumor microenvironment. This Viewpoint aims to give an update on recent developments in
immunotherapy for solid tumors and highlights progress in translational research and
clinical practice.
resistance to ICB occurs frequently due to tumor-intrinsic alterations or extrinsic factors in the
tumor microenvironment. This Viewpoint aims to give an update on recent developments in
immunotherapy for solid tumors and highlights progress in translational research and
clinical practice.
Immune checkpoint blockade (ICB) has revolutionized cancer treatment. However, resistance to ICB occurs frequently due to tumor-intrinsic alterations or extrinsic factors in the tumor microenvironment. This Viewpoint aims to give an update on recent developments in immunotherapy for solid tumors and highlights progress in translational research and clinical practice.
AAAS